Healthcare · Profile from Healthcare Research Companion
Intuitive Surgical, Inc.
The company that took a military telesurgery research project and made it the standard of care for robot-assisted soft-tissue surgery. Intuitive's da Vinci system has been the dominant surgical robot for a quarter of a century. Its real business is the procedure: each da Vinci operation consumes proprietary instruments and accessories, and each installed system carries a service contract. Roughly three-quarters of revenue is recurring. That razor-and-blade model, a huge base of trained surgeons and a long head start on evidence have made Intuitive one of the most valuable medical device companies in the world. They have also brought product liability litigation, an FDA warning letter and antitrust suits over the way it limits instrument reuse.
At a glance
- Founded
- 1995, Mountain View/Sunnyvale, California, to commercialise robotic telesurgery technology licensed from SRI International
- Founders
- Frederic Moll (physician), John Freund and Robert Younge
- Headquarters
- Sunnyvale, California
- Ownership / structure
- Public company, Nasdaq: ISRG (IPO June 2000); widely held, no controlling shareholder
- Leadership (2026)
- Dave Rosa, CEO (from July 2025); Gary Guthart, executive chair (CEO 2010–2025); Jamie Samath, CFO (verify current titles)
- Segment and buyer
- Device & diagnostics (capital equipment plus consumables). Buyers are hospital capital committees and, increasingly, ambulatory surgery centers; surgeons choose; payers reimburse the procedure, not the robot
- Scale
- 2025 revenue ~$10.06bn (+21%); ~3.15m da Vinci procedures (+18%); installed base ~11,106 da Vinci systems at end 2025 (1,721 placed in 2025, 870 of them da Vinci 5); roughly 1,000 Ion systems (company 10-K). Q3 2026: revenue ~$3.05bn (+22%), ~906,000 procedures (+14%), installed base 12,094 (reported)
- Capital / market cap
- IPO on Nasdaq 13 June 2000 (proceeds not re-checked); self-funded since; no meaningful debt; large buybacks; market cap roughly $150–200bn through 2025–26 (approximate, from share price; shares fell ~8% on the Q3 2026 release)
- Signature moves (incl. failures)
- SRI licence and da Vinci clearance (1995–2000); Computer Motion merger ending the patent war (2003); urology and gynecology beachhead (2001–05); 2013 FDA warning letter and product liability wave; da Vinci Xi and general surgery expansion (2014); Ion lung biopsy platform (2019); EndoWrist usage limits and antitrust litigation (2019–2026); da Vinci 5 (2024)
8 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
2000
SRI Licence and First FDA Clearance
Founding / launch / IPO
2003
Computer Motion Merger
Merger
2005
Urology and Gynecology Beachhead
Market expansion (indication-led growth)
2013
FDA Warning Letter and Liability Wave
Regulatory action and litigation (crisis response)
2014
da Vinci Xi and General Surgery
Launch (new platform) and market expansion
2019
EndoWrist Limits and Antitrust Suits
Pricing policy defended in litigation
2019
Ion Lung Biopsy Platform
Launch (second platform, new field)
2024
da Vinci 5 Launch
Launch (fifth-generation multiport platform)